Get the Stockscreener App
11.13
0.91%
0.10
After Hours:
11.13
Nextcure Inc stock is traded at $11.13, with a volume of 55,396.
It is up +0.91% in the last 24 hours and down -10.17% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$11.03
Open:
$11.19
24h Volume:
55,396
Relative Volume:
1.57
Market Cap:
$39.63M
Revenue:
-
Net Income/Loss:
$-55.84M
P/E Ratio:
-0.6326
EPS:
-17.5951
Net Cash Flow:
$-49.61M
1W Performance:
+4.21%
1M Performance:
-10.17%
6M Performance:
+81.65%
1Y Performance:
+2,785%
1-Day Range:
$10.46
$11.73
1-Week Range:
$10.31
$11.73
52-Week Range:
$0.224
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
11.13 | 39.27M | 0 | -55.84M | -49.61M | -17.60 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 110.47B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.67B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 46.53B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 43.81B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.36B | 606.42M | -1.28B | -997.58M | -6.403 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
NextCure Gets FDA Fast Track for SIM0505 in Ovarian Cancer - National Today
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - Bitget
Resistance Check: Is NextCure Inc exposed to currency risksMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Trend Report: Will Investcorp Credit Management BDC Inc Preferred Security outperform tech stocksWeekly Investment Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
NXTC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Buyout Rumor: Will American Tower Corporation stock go up in YEAR2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
NXTC Should I Buy - Intellectia AI
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 - The Manila Times
Phase 1 cancer drug abstract lands ASCO 2026 slot in Chicago - Stock Titan
Price Action: Is Oriental Culture Holding LTD stock a top performer YTD2026 Selloffs & Daily Entry Point Trade Alerts - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
BLRX PE Ratio & Valuation, Is BLRX Overvalued - Intellectia AI
Bond Watch: Is NextCure Inc stock showing strong momentumQuarterly Portfolio Summary & Verified Entry Point Signals - baoquankhu1.vn
NextCure, Inc.Common Stock (NQ: NXTC - FinancialContent
Retail Trends: Why is GGNPRB stock going downLong Setup & Smart Investment Allocation Insights - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
NIVFPrice, Charts & Blockchain Insights - Intellectia AI
ITVI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MMMM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Buy Signal: Is NextCure Inc a defensive stockQuarterly Trade Review & Growth-Oriented Investment Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Aug Action: Is CF Bankshares Incs growth already priced in2026 Chart Watch & Proven Capital Preservation Methods - baoquankhu1.vn
Published on: 2026-03-22 18:56:49 - baoquankhu1.vn
BOLD Technical Analysis & Price Forecast - Intellectia AI
LOW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
HTH Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
BKT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BSX Technical Analysis & Price Forecast - Intellectia AI
CULP Should I Buy - Intellectia AI
Travel Stocks: Is NextCure Inc stock good for income investorsTrade Risk Assessment & AI Forecast Swing Trade Picks - baoquankhu1.vn
NextCure Inc Stock (ISIN: US65343E1082) Faces Analyst Downgrade Amid Biotech Sector Headwinds - AD HOC NEWS
NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment - MSN
NextCure Provides Business Update and Reports Full Year 2025 Financial Results - The Manila Times
NextCure Inc reports results for the quarter ended September 30Earnings Summary - TradingView
NextCure 10-K: $0 Revenue, $(19.65) EPS reported - TradingView
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NXTC SEC FilingsNextcure 10-K, 10-Q, 8-K Forms - Stock Titan
NextCure, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
NextCure Inc expected to post a loss of $2.42 a shareEarnings Preview - TradingView
Hedge Fund Bets: Is NextCure Inc stock good for income investorsJuly 2025 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
NXTC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World
Published on: 2026-02-26 09:55:29 - baoquankhu1.vn
NextCure (NASDAQ:NXTC) Stock Price Down 3.7% – What’s Next? - Defense World
Can NextCure Inc. stock double in next 5 yearsWeekly Investment Report & Technical Entry and Exit Tips - mfd.ru
Squadron funds disclose 9.99% holding in NextCure (NXTC) common stock - Stock Titan
Will The Allstate Corporation stock benefit from green energy trendsIPO Watch & Weekly Return Optimization Alerts - mfd.ru
NXTC Technical Analysis & Stock Price Forecast - Intellectia AI
Is FSLR stock a top pick in earnings seasonMarket Trend Summary & Precise Swing Trade Alerts - mfd.ru
Street Watch: Is NextCure Inc stock showing strong momentumGap Down & Community Verified Trade Signals - baoquankhu1.vn
Cancer index surges 72% as Terns, Olema lead gains - BioWorld MedTech
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):